These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32272093)

  • 1. Vaccines to prevent genital herpes.
    Egan K; Hook LM; LaTourette P; Desmond A; Awasthi S; Friedman HM
    Transl Res; 2020 Jun; 220():138-152. PubMed ID: 32272093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.
    Awasthi S; Hook LM; Shaw CE; Friedman HM
    Hum Vaccin Immunother; 2017 Dec; 13(12):2785-2793. PubMed ID: 28481687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4
    Srivastava R; Roy S; Coulon PG; Vahed H; Prakash S; Dhanushkodi N; Kim GJ; Fouladi MA; Campo J; Teng AA; Liang X; Schaefer H; BenMohamed L
    J Virol; 2019 May; 93(9):. PubMed ID: 30787156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
    Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
    JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
    Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.
    Hook LM; Awasthi S; Dubin J; Flechtner J; Long D; Friedman HM
    Vaccine; 2019 Jan; 37(4):664-669. PubMed ID: 30551986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of prophylactic vaccines for genital and neonatal herpes.
    Jones CA; Cunningham AL
    Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.
    Egan KP; Hook LM; Naughton A; Pardi N; Awasthi S; Cohen GH; Weissman D; Friedman HM
    PLoS Pathog; 2020 Jul; 16(7):e1008795. PubMed ID: 32716975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenge of developing a herpes simplex virus 2 vaccine.
    Dropulic LK; Cohen JI
    Expert Rev Vaccines; 2012 Dec; 11(12):1429-40. PubMed ID: 23252387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.
    LaTourette PC; Awasthi S; Desmond A; Pardi N; Cohen GH; Weissman D; Friedman HM
    Vaccine; 2020 Nov; 38(47):7409-7413. PubMed ID: 33041105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection.
    Egan K; Hook LM; Naughton A; Friedman HM; Awasthi S
    Hum Vaccin Immunother; 2020 Sep; 16(9):2109-2113. PubMed ID: 32347775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
    Awasthi S; Shaw C; Friedman H
    Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
    Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
    PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
    PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating protective immunity against genital herpes.
    Shin H; Iwasaki A
    Trends Immunol; 2013 Oct; 34(10):487-94. PubMed ID: 24012144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.
    Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L
    J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.